StemRIM (4599.T)
JPY 317.0
(-0.63%)
JPY 317.0
(-0.63%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -8.41 Billion JPY | 17.69% |
| 2023 | -10.21 Billion JPY | -15.1% |
| 2022 | -8.87 Billion JPY | 12.68% |
| 2021 | -10.16 Billion JPY | 4.69% |
| 2020 | -10.66 Billion JPY | -329.4% |
| 2019 | -2.48 Billion JPY | -34.74% |
| 2018 | -1.84 Billion JPY | -103.84% |
| 2017 | -904.31 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -9.18 Billion JPY | 6.17% |
| 2024 Q1 | -9.78 Billion JPY | 4.21% |
| 2024 Q4 | -8.41 Billion JPY | 3.76% |
| 2024 Q3 | -8.73 Billion JPY | 4.85% |
| 2023 Q3 | -7.91 Billion JPY | 5.83% |
| 2023 Q2 | -8.4 Billion JPY | 2.15% |
| 2023 Q4 | -10.21 Billion JPY | -29.04% |
| 2023 Q1 | -8.59 Billion JPY | 3.2% |
| 2023 FY | -10.21 Billion JPY | -15.1% |
| 2022 Q3 | -9.11 Billion JPY | 6.2% |
| 2022 Q2 | -9.71 Billion JPY | 1.56% |
| 2022 Q1 | -9.86 Billion JPY | 2.93% |
| 2022 Q4 | -8.87 Billion JPY | 2.58% |
| 2022 FY | -8.87 Billion JPY | 12.68% |
| 2021 Q4 | -10.16 Billion JPY | -11.33% |
| 2021 FY | -10.16 Billion JPY | 4.69% |
| 2021 Q1 | -10.24 Billion JPY | 3.93% |
| 2021 Q3 | -9.13 Billion JPY | 8.32% |
| 2021 Q2 | -9.95 Billion JPY | 2.79% |
| 2020 Q4 | -10.66 Billion JPY | -16.78% |
| 2020 Q2 | -9.81 Billion JPY | 1.9% |
| 2020 Q1 | -10 Billion JPY | -302.84% |
| 2020 FY | -10.66 Billion JPY | -329.4% |
| 2020 Q3 | -9.13 Billion JPY | 6.96% |
| 2019 Q4 | -2.48 Billion JPY | 8.24% |
| 2019 Q3 | -2.7 Billion JPY | 0.0% |
| 2019 FY | -2.48 Billion JPY | -34.74% |
| 2018 FY | -1.84 Billion JPY | -103.84% |
| 2017 FY | -904.31 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 1232.265% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -641.66% |
| GNI Group Ltd. | -17.93 Billion JPY | 53.105% |
| Linical Co., Ltd. | -4.46 Billion JPY | -88.426% |
| Trans Genic Inc. | -221.16 Million JPY | -3702.522% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | -91.396% |
| Soiken Holdings Inc. | -4.79 Billion JPY | -75.573% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 686.661% |
| AnGes, Inc. | -3.79 Billion JPY | -121.447% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -1898.541% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 133.764% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -1588.233% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -1703.378% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -210.776% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -345.398% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -756.292% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | -147.57% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -712.911% |
| Kidswell Bio Corporation | 343.58 Million JPY | 2547.692% |
| PeptiDream Inc. | 3.29 Billion JPY | 355.468% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -764.699% |
| Ribomic Inc. | -2.09 Billion JPY | -300.525% |
| SanBio Company Limited | -3.78 Billion JPY | -121.916% |
| Healios K.K. | -2.19 Billion JPY | -284.018% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -790.079% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -220.485% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -493.481% |
| CellSource Co., Ltd. | -4.68 Billion JPY | -79.567% |
| FunPep Company Limited | -1.79 Billion JPY | -368.947% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -293.636% |
| Stella Pharma Corporation | -1.11 Billion JPY | -651.293% |
| TMS Co., Ltd. | -3.44 Billion JPY | -144.006% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | -51.376% |
| Cuorips Inc. | -5.56 Billion JPY | -51.232% |
| K Pharma,Inc. | -3.26 Billion JPY | -157.469% |
| Takara Bio Inc. | -32.2 Billion JPY | 73.884% |
| ReproCELL Incorporated | -2.93 Billion JPY | -186.146% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -1172.392% |
| StemCell Institute Inc. | -2.83 Billion JPY | -196.465% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -306.999% |
| CellSeed Inc. | -2.01 Billion JPY | -317.983% |